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Objective: Successful endovascular aortic aneurysm repair depends on exclusion and spontaneous thrombosis of the
aneurysm sac. The need for chronic postoperative anticoagulation therapy could limit the applicability of this technology
with delay or prevention of sac thrombosis resulting in endoleak formation and altered remodeling of the aneurysm sac.
The purpose of this study was the determination of whether chronic therapeutic anticoagulation therapy with warfarin
was associated with an increased incidence rate of early or delayed postoperative endoleaks or altered rates of reduction
in aneurysm sac maximum diameter.
Methods: Two hundred thirty-two consecutive patients underwent abdominal aortic endografting during a 32-month
period. The data were recorded prospectively with a current mean follow-up period of 18 months. The patients with
endoleaks identified with 30-day postoperative computed tomographic scan angiograms subsequently underwent
selective arteriography to characterize the source. The patients who underwent chronic warfarin therapy that resulted in
a therapeutic internationalized normalized ratio comprised the study group. The control group was defined as all the
patients with healthy coagulation profiles.
Results: Thirty-six patients (15%) were undergoing warfarin therapy after surgery, and their conditions were chronically
maintained with a therapeutic international normalized ratio. Forty-three patients (18%) had endoleaks on 30-day
computed tomographic scan angiographic results. There were 39 patients with type II endoleaks and four patients with
type I endoleaks. None of the type I endoleaks occurred in patients who were undergoing warfarin therapy, and all
endoleaks were repaired with either proximal or distal covered extensions. At 30 days, seven patients (19.4%) undergoing
chronic warfarin therapy had type II endoleaks as compared with 36 controls (18.4%; P  .798). Four patients had
delayed type II endoleaks develop, two in the control group and two in the warfarin group (P  .3). Ten control
individuals (31%) had spontaneous resolution of type II endoleaks develop, whereas spontaneous endoleak thrombosis
was not observed in the warfarin group (P  .33). Aneurysm sac remodeling assessed with mean percent reduction in
maximum sac diameter at 12 months revealed a statistical difference between the control group (17.5%) and the warfarin
group (7.6%; P  .04).
Conclusion: Warfarin treatment is not associated with an increase in the incidence rate of early or delayed postoperative
endoleaks. However, the rate of reduction in maximum aneurysm sac diameter after aortic endografting is slower in
patients who undergo therapeutic warfarin therapy at 1-year follow-up examination, a statistically significant difference
from the control group. In addition, type II endoleaks may be less likely to undergo spontaneous thrombosis in patients
who undergo warfarin therapy. (J Vasc Surg 2002;35:679-85.)
Successful endovascular aortic aneurysm repair depends
on secure fixation of the endograft at the proximal and
distal attachment sites. In addition, the endovascular con-
cept is predicated on the assumption that the aneurysm sac
will undergo spontaneous thrombosis that will result in
complete exclusion. Incomplete sac thrombosis may be the
result of various types of endoleaks, including type II
endoleaks, which are created by patent branches that arise
from the aneurysm sac.1 Systemic anticoagulation therapy
could potentially inhibit the spontaneous thrombosis of the
aneurysm sac, thus perpetuating systemic flow through
aneurysm sac channels that connect the endoleak inflow
and outflow collateral vessels. Type II endoleak has been
reported to have an incidence rate of 16% to 20%2,3 and
results in continued pressurization of the sac.4,5 Immediate
postprocedure endoleak rates are even higher, which indi-
cates that spontaneous thrombosis of endoleaks with the
passage of time is an important factor in successful endo-
vascular aneurysm repair.
Patients who chronically undergo postoperative antico-
agulation therapy potentially represent a disadvantaged
population for successful endovascular repair because ther-
apeutic doses of warfarin could theoretically inhibit spon-
taneous sac thrombosis and increase the incidence of type II
endoleaks. The purpose of this study was the determination
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of whether chronic therapeutic anticoagulation therapy
with warfarin in the postoperative setting was associated
with an increased incidence of early or delayed endoleaks
and thus compromised the results of endovascular aortic
aneurysm repair. In addition, we aimed to investigate the
hypothesis that chronic warfarin treatment could influence
sac remodeling.
METHODS
We performed a retrospective review of 232 consecu-
tive patients who underwent abdominal aortic aneurysm
(AAA) endografting during a 32-month period. The mean
follow-up period was 18 months. The data were collected
prospectively because most of the patients were enrolled in
Food and Drug Administration (FDA)–approved Phase II
Clinical Trials. The preoperative assessment included
marker catheter aortic and pelvic arteriograms, unenhanced
computed tomographic (CT) scans, and 3-mm cut CT scan
angiograms. The inclusion and exclusion criteria were an-
atomically based and defined for each specific type of aortic
endograft. The study group consisted of patients who were
undergoing chronic warfarin therapy after surgery that
resulted in a therapeutic international normalized ratio
(INR) of greater than 2.0. The control group included all
the patients with a healthy coagulation profile.
Postoperative CT scan angiography included delayed
acquisitions (60 seconds after injection) for the detection of
small endoleaks. All the patients with a persistent endoleak
identified on a 30-day postoperative CT scan angiogram
underwent selective arteriography to characterize the
source. Our approach to endoleak angiography is described
in Fig 1 and begins with an abdominal aortogram in two
views and then consists of power injector arteriograms with
a pigtail positioned at all attachment sites. Selective cathe-
terization of the superior mesenteric and internal iliac ar-
teries is performed after the exclusion of an attachment site
endoleak, and filming is carried through the venous phase.
In the setting of an endoleak that has persisted for 30 days,
our main concern has been to rule out the presence of a
type I endoleak. With this rationale, selective and supra-
selective arteriograms were used for the accurate diagnosis
of the source of all endoleaks noted to persist beyond 30
days after endovascular AAA repair. When technically fea-
sible, this method was also used therapeutically for the
obliteration of endoleaks from collateral branches.2 Out-
come parameters included group comparisons of endoleak
rates by type, timing, and natural history. In addition, sac
remodeling was assessed as percentage change in maximum
sac diameter at 6 and 12 months after surgery. Maximum
aneurysm sac diameter was determined manually from
cross-sectional CT scan angiogram results. Statistical differ-
ences were evaluated with either 2 test or Student t test as
indicated depending on the variable type. All the calcula-
tions were performed with Primer of Biostatistics for Win-
dows 95 version 4.0 (Stanton A Glantz, McGraw-Hill, Inc,
New York, NY).
RESULTS
Two hundred sixteen of 232 patients (93.1%) in this
series showed aneurysm sac shrinkage, 11 (4.7%) showed
aneurysm sac stabilization, and only five (2.2%) showed an
increase in maximum sac diameter, at a mean follow-up
period of 18 months and with prospective definitive treat-
ment of all detected endoleaks persistent beyond 30 days.
There were neither clinically nor statistically significant
differences in this distribution according to history of en-
doleak or treatment with warfarin at this point in the
follow-up period. However, these questions will need to be
carefully reevaluated with increasing numbers of patients
and longer follow-up periods. There was no clinical or
statistically significant influence of either warfarin therapy
or endoleak on the number of patients that showed in-
creases in aneurysm sac. Endoleak was not a significant
variable affecting these data because in our series we treated
Fig 1. Endoleak angiography. Left reveals power injector run at iliac attachment site, middle is selective injection of
superior mesenteric artery (SMA), and right shows type II endoleak from patent inferior mesenteric artery.
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all endoleaks at a much earlier follow-up period (1 month).
In this series, there were no conversions to open repair after
successful endovascular repair.
Although statistical significance was not achieved in the
differences in endoleak rates, late endoleaks were five times
as common (1% versus 5.6%) in the warfarin group, and
spontaneous resolution of type II endoleaks was not ob-
served in the warfarin group, whereas it was seen in 10 of
the control group endoleaks (31%). Thus, the possibility of
type II statistical error should be considered, particularly
because the reduction in aneurysm size was significantly
slower in the warfarin group.
There were no statistical differences in the control
versus the warfarin group in regard to mean age, gender
distribution, smoking history, diabetes mellitus, hyperten-
sion, associated cardiac, pulmonary, renal, or hepatic co-
morbidity, and aspirin use. Most cases were performed with
bifurcated graft designs, and 32 cases (14%) needed aorto-
uniiliac designs that included femoral-femoral bypass graft,
ipsilateral hypogastric artery embolization, and contralat-
eral common iliac artery embolization (Table). Talent en-
dografts (World Medical Inc/Medtronic, Sunrise, Fla)
were placed in 125 cases (53%), and all cases were per-
formed with a Phase II FDA Clinical Trial. Ancure/EVT
(Endovascular Technology/Guidant, Menlo Park, Calif)
endografts were placed in 43 cases (19%) and included
procedures performed as part of the Phase III cohort and
after FDA device approval. The AneuRx (Medtronic, Santa
Rosa, Calif) endograft procedures (n  37; 16%) were all
performed after FDA device approval. The Cook (India-
napolis, Ind) endografts (n  23; 10%) were Zenith bifur-
cated devices implanted during Phase II trials. The Cordis
(Warren, NJ) endografts were implanted with a FDA Phase
I protocol. Essentially all the aortouniiliac endografts were
Talent designs, although there were five Ancure aortouni-
iliac designs in this series. The control group included 196
patients (85%), and the study group, with chronic thera-
peutic warfarin treatment, consisted of 36 patients (15%).
There were 43 endoleaks (18.5%) identified at 30 days with
CT scan angiography (Table). Of these, four type I en-
doleaks were subsequently identified with selective en-
doleak angiography, and all occurred in the control group.
All four were repaired with proximal or distal covered
extensions.
The Table presents an endoleak summary by endograft
type and design. Endoleaks were observed in Talent (n 
24; 19%), AneuRx (n  6; 16%), and EVT (n  13; 30%)
cases. Endoleaks were further stratified into the control
group versus the warfarin group, and there were no statis-
tical trends. The absence of endoleaks in the AneuRx cases
with warfarin therapy and in the Cook and Cordis en-
dografts is not statistically significant. Talent endoleaks
were further analyzed by bifurcated (n  16; 16%) versus
aortouniiliac (n  8; 30%) endograft designs and again
stratified into the control group versus the warfarin group.
There were no statistical differences.
There were 39 type II endoleaks (16.8%) identified at
30 days with CT scan angiography (Table). Within the
control group (n  196), there were 32 type II endoleaks
(16.3%), and within the warfarin group (n  36), there
were seven (19.4%). This difference was not statistically
significant (P  .84). Ten type II endoleaks (31%) in the
control group were noted to undergo spontaneous resolu-
tion. However, none of the endoleaks in the warfarin group
Endoleak summary
Control group P value* Warfarin group Total
No. patients 196 .05 36 232
30-day endoleaks by type
Type I 4 (2%) NS 0 4 (1.7%)
Type II 32 (16%) NS 7 (19%) 39 (16.8%)
All other types 0 NS 0 0
Total 36 (18.4%) NS 7 (19.4%) 43 (18.5%)
Spontaneous Type II endoleak resolution 10 (31%) .33 0
Delayed endoleaks (all type II) 2 (1%) .30 2 (5.6%) 4 (1.7%)
Endoleaks by endograft design
(patients; endoleaks)
Talent† (total) 103; 19 (18%) NS 22; 5 (23%) 125; 24 (19%)
Talent† (aortouniiliac) 20; 6 (30%) NS 7; 2 (29%) 27; 8 (30%)
Talent† (bifurcated) 83; 13 (16%) NS 15; 3 (20%) 95; 16 (16%)
AneuRx‡ 31; 6 (19%) NS 6; 0 37; 6 (16%)
EVT§ 39; 11 (28%) NS 4; 2 (50%) 43; 13 (30%)
Cook 21; 0 NS 2; 0 23; 0
Cordis¶ 2; 0 NS 2; 0 4; 0
*P values determined with 2 test, with significance at P  .05.
†World Medical Inc./Medtronic, Sunrise, Fla.
‡Medtronic, Santa Rosa, Calif.
§Endovascular Technology/Guidant, Menlo Park, Calif.
Cook, Indianapolis, Ind.
¶Cordis, Warren, NJ.
NS, Not significant.
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spontaneously sealed, a difference that was not statistically
significant (P  .33).
Delayed endoleaks developed in four patients, and all
were type II in origin. These were patients without evi-
dence of an endoleak initially who later had leaks develop.
Two cases (1%) were in the control group, and two (5.6%)
were in the warfarin group (P .30). An example of one of
the delayed type II endoleaks is presented in Fig 2. This
patient was in the warfarin group and had initially under-
gone treatment with a Talent aortouniiliac graft and a
right-to-left femoral-femoral bypass grafting procedure
with coil embolization of the left common iliac artery. At
the 18-month follow-up examination, a new endoleak was
observed with CT scan angiography. Endoleak angio-
graphic results revealed retrograde flow past the coils and
reperfusion of the aneurysm sac. The placement of addi-
tional coils in the left common iliac artery successfully
treated this endoleak. Occluder plugs from the Talent
aortouniiliac system are not yet approved for use or study in
the United States. In our experience, coil embolization is a
reasonable means of occluding the ipsilateral hypogastric
artery and the contralateral common iliac artery after aor-
touniiliac endovascular repair. We have successfully used
this method in 32 patients (14%) without a significant
increase in endoleak rates and without any untoward side
effects.
Aneurysm sac remodeling, defined as percentage
change in sac diameter at 6 and 12 months, is depicted in
Fig 3 (data shown as mean  the standard error of the
mean). At 6 months, the mean decrease in sac diameter
within the control group was 14%  0.02%, as compared
with 11%  0.02% in the warfarin group (P  .42). At 12
months, the mean decrease in sac diameter within the
control group was 17% 0.01%, as compared with 7.6%
0.03% in the warfarin group. This difference at 12 months
was statistically significant (P  .04), which indicated a
slower rate of reduction in the maximum aneurysm sac
diameter for the warfarin group at 1 year of follow-up
examination.
DISCUSSION
Aneurysm sac thrombosis with remodeling and shrink-
age is the goal of endovascular AAA repair. Chronic thera-
peutic warfarin use could possibly compromise the results
of the procedure by potentially altering the physiology of
collateral flow and pressure transmission to the aortic wall.
In 1999, Torsello et al6 described a case of aneurysm
rupture 16 months after treatment with an endograft. The
patient had no evidence of an endoleak and was undergoing
therapeutic warfarin therapy for an aortic valve replace-
ment. The rupture was preceded by aneurysm sac enlarge-
ment noted with CT scanning 7 months after surgery.
These authors concluded that aneurysm sac expansion even
in the absence of an endoleak should represent failed exclu-
sion and anticoagulation therapy can be an important factor
in failure after endovascular repair.
Fig 2. Delayed type II endoleak occurring in warfarin group 18 months after placement of Talent aortouniiliac graft
(World Medical Inc/Medtronic, Sunrise, Fla) and right-to-left femoral-femoral bypass graft with coil embolization of
left common iliac artery. Endoleak angiography revealed retrograde flow (arrow) past coils and reperfusion of aneurysm
sac.
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However, despite common sense, clinical perception,
and sparse anecdotal reports, no prior study has specifically
been aimed at formally evaluating the potential outcome
effects of warfarin treatment in the setting of endovascular
repair of aortic aneurysms. This work represents the first
report of chronic warfarin treatment after aortic endograft-
ing and its associated endoleak rates and rates of aneurysm
sac reduction. We found that although early and late en-
doleak rates are not significantly different in control indi-
viduals versus patients undergoing warfarin treatment at
this midterm follow-up period, there may be a physiologi-
cally significant difference in aneurysm remodeling associ-
ated with warfarin treatment. Warfarin treatment was asso-
ciated with slower rates of aneurysm shrinkage after aortic
endografting.
In this series, the great majority of patients have had
either aneurysm sac shrinkage or stabilization. There were
five patients in the series who were noted to have increasing
aneurysm sac diameters. Only two of these patients were
also noted to have a type II endoleak (3.03 and 2.07
mm/year increases). Both cases were successfully treated,
and after endoleak embolization, the aneurysm sacs have
been shrinking. The cause for aneurysm growth in the three
other patients remains unknown. Thus far, we have not
opted conversion to open repair in any of these patients
because maximum diameter increases have been minimal
(range, 0.74 to 1.13 mm/year). Only one of these five
patients is undergoing chronic treatment with warfarin
(0.74 mm/year increase in maximum diameter), and this
patient did not have a demonstrable endoleak.
In spite of the fact that chronic warfarin use in the
elderly population with cardiovascular disease is relatively
common (15% of the 232 patients reported in our study),
there are no other reports in the literature that assess the
impact of warfarin use on the results of endovascular repair.
Shah and colleagues7-9 have published a large series of
AAAs treated with exclusion and bypass grafting, a model
that closely approximates exclusion by endovascular repair.
These authors identified persistent flow in the excluded sac
in 48 of 1218 patients, 27 of whom underwent surgical
revision (seven for rupture). There were no identifiable
factors predictive of persistent flow, although long-term
anticoagulation therapy approached significance (P 
.056). The average time from original exclusion and bypass
grafting to secondary intervention was more than 4 years.
These authors concluded that exclusion and bypass grafting
is not a definitive procedure and that expansion of the
aneurysm sac may be the only reliable predictor of patent
sacs.
In our series of 232 consecutive endovascular repairs,
chronic therapeutic warfarin therapy did not result in an
increased incidence rate of early or delayed postoperative
Fig 3. Aneurysm sac remodeling defined as percentage reduction in maximum sac diameter at 6 and 12 months for
control and warfarin groups (data shown as mean standard error of mean). Difference at 12 months was statistically
significant (P  .04), which suggests slower rate of reduction in maximum sac diameter for warfarin group at 1-year
follow-up examination.
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type II endoleaks as can be detected with current standard
radiographic techniques. However, we have observed
spontaneous resolution of type II endoleaks in 31% of the
cases, and this phenomenon was only observed to occur in
the control group, not in patients undergoing warfarin
therapy. Although this observation was not statistically
significant, it is possible that this is a type II statistical error
and further study with pooled data from different institu-
tions could prove conclusive. We believe that a particular
strength of this analysis is that all endoleaks noted at 30
days were studied with selective angiography for the deter-
mination of the source, rather than the characterization of
the endoleaks with CT scan results alone. However, it must
be noted that this is a retrospective study and that the total
number of patients for the subgroup analysis may not be
sufficient for definitive conclusions. But the findings clearly
suggest that warfarin treatment is an important factor,
although it is not necessarily directly related to endoleak
rates on early and midterm follow-up examination. The
endoprosthesis devices that were used were fairly heteroge-
neous, but one would not anticipate these issues to be
device specific. In addition, the mean follow-up period of
18 months represents a midterm assessment of the data
regarding this important question under study. However,
despite these words of caution in the final interpretation of
the data presented in this work, these novel findings should
be considered in the evaluation for endovascular AAA
repair of a patient who will need chronic warfarin treat-
ment.
In this series, all the type II endoleaks found to be
persistent after 1 month were treated with either emboliza-
tion of the collateral lending inflow to the endoleak or
embolization of the nidus of endoleak flow within the
aneurysm sac.2,4,10 Because type II endoleaks are usually
perpetuated by more than one set of potential inflow and
outflow pair, we have noted a significant rate of recurrence
needing multiple embolizations.10 The approach of embo-
lizing the sac nidus has the promise of being more durable
by interrupting the inflow to outflow channel within the sac
itself.10 The rationale for this fairly aggressive approach is
that although a significant percentage of type II endoleaks
spontaneously disappear, the time interval for endoleak
thrombosis and the response of the aneurysm sac diameter
varies widely.
Although most groups fear rupture from type I and
type III endoleaks, because these represent technical or
devise failures, many groups feel comfortable following
type II endoleaks, for these are related to patient anatomy.
However, the risk of aneurysm rupture in different types of
endoleaks is really unknown. Thus, investigators arbitrarily
follow various types of endoleaks for time intervals that
range from days to months to more than 1 year. Our group
has been impressed by reported in vitro, well-controlled,
physiologic experiments in which even a small collateral
vessel (0.410 mm) can maintain systemic pressure within an
excluded aneurysm sac.11 More strikingly, we have mea-
sured systemic pulsatile waveforms within endovascularly
excluded aneurysm sacs in patients with type II en-
doleaks.2,4,5,10 Therefore, until we learn more about the
effectiveness and durability of this new method of aneurysm
repair in the presence of endoleaks, our philosophy has
been that a persistent endoleak represents an incomplete
aneurysm treatment and thus ongoing rupture risk.
We acknowledge that our mean follow-up period of 18
months is relatively short given the average time to secondary
intervention of more than 4 years reported by Shah and
colleagues6 with their exclusion and bypass grafting tech-
nique. Clearly, long-term follow-up examination is needed for
the determination of whether the chronically anticoagulated
endovascular population is indeed disadvantaged. It is partic-
ularly concerning that we identified patients in our study who
had no evidence of an endoleak initially and were found to
have had endoleaks develop in later follow-up examination.
Although the purpose of this study was to determine
whether chronic therapeutic warfarin therapy increased the
incidence rate of early or late postoperative endoleaks, it is
likely that the presence or absence of an endoleak alone may
not be the most accurate predictor of long-term outcome.
Wolf et al12 reported that the presence of an endoleak is
unreliable in the prediction of changes in aneurysm diam-
eter, although aneurysm diameter in patients without en-
doleaks had a higher rate of decrease and aneurysm diam-
eter in patients with persistent endoleaks did not change in
mean diameter. Furthermore, Zarins et al13 reported that
the presence or absence of endoleak on CT scan results
before hospital discharge did not predict survival or aneu-
rysm rupture rates after endovascular repair with the An-
euRx endograft. Schunn et al14 concluded that although
persistent endoleaks tend to be associated with aneurysm
growth, aneurysm shrinkage is sometimes also observed.
Armon et al15 reported their experience and observed
aneurysm growth despite no evidence of an endoleak on
CT scan results. Furthermore, Resch et al16 noted that
persistent endoleak was associated with either increasing or
unchanged sac diameters. Sac shrinkage after endografting
was observed to stop after 18 months, and the indication
of late failure in the absence of endoleak might be sac
enlargement.
Along these same lines, the only statistically significant
finding in our study was the comparison of sac remodeling
between the control and warfarin groups at the 12-month
follow-up examination. We defined sac remodeling as the
percentage change in maximum sac diameter, and greater
reductions were observed in the control group, which
suggests that sac shrinkage may be negatively impacted by
chronic warfarin use. Long-term follow-up examination is
needed to confirm this significant observation.
The warfarin group did not have a statistically signifi-
cant increased rate of early or late type II endoleaks. How-
ever, other observations, such as no spontaneous thrombo-
sis, higher rate of delay endoleaks, and slower rate of sac
shrinkage, although not all statistically significant, suggest
that warfarin treatment may adversely impact these indirect
measures of success after endovascular AAA repair. Clearly,
longer term follow-up examination and increased numbers
of patients are needed to further understand this potentially
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significant physiologic impact of chronic therapeutic war-
farin treatment for these patients. In addition, as technol-
ogy makes feasible the routine assessment of serial aneu-
rysm sac volumes and surface area, in addition to maximum
sac diameter, these variables may prove more sensitive in
the long-term follow-up examination of patients after en-
dovascular repair of aortic aneurysms. With increasingly
sensitive measures of aneurysm remodeling, it may become
easier to show definitive differences in the physiology of
aneurysm remodeling with and without warfarin treatment.
In conclusion, chronic therapeutic warfarin therapy did
not result in an increased incidence rate of early or delayed
postoperative endoleaks. Aneurysm sac remodeling in pa-
tients who undergo chronic warfarin therapy appears to be
statistically different from control groups who show a
slower rate of shrinkage. Whether spontaneous resolution
of type II endoleaks is precluded by chronic warfarin use
requires further study.
We thank Megan Chew and Amy McBride for their
assistance in the preparation of this manuscript.
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